Search Results
The COMMANDS study: luspatercept versus epoetin alfa for ESA-naïve lower-risk MDS-associated anemia
COMMANDS: luspatercept vs epoetin alfa for anemia in ESA-naive LR-MDS
COMMANDS: luspatercept versus epoetin alfa in LR-MDS-associated anemia - results & caveats
COMMANDS trial: luspatercept vs epoetin alfa in lower-risk MDS
COMMANDS study: efficacy & safety results and biomarker analysis
Luspatercept for the treatment of patients with lower-risk MDS and ESA failure
Sangeetha Venugopal, MD, Weighs in on Results from the Phase III COMMANDS Trial
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification
Real-world data on the efficacy of luspatercept in LR-MDS
Recent advances in the treatment of LR-MDS: COMMANDS and IMerge trial data
Addressing Treatment Gaps Among Patients with MDS-Associated Anemia
The promise of luspatercept for the treatment of lower-risk MDS
